MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabete...(s listed in the table below. ...),Health

Teplizumab Clinical Trials

Study Brief Description Additional Information

Protege trial Global Phase 2/3 trial http://www.protegediabetes.com

for patients with http://www.clinicaltrials.gov

recent-onset type 1 (search for Protege)

diabetes mellitus (less

than or equal to 12

weeks from symptoms)

ages 8-35 with treatment

at the start of the

study and again at

six months

AbATE trial Led by Dr. Kevan Herold http://www.abatetrial.org

of Yale University, http://www.clinicaltrials.gov

this Phase 2 trial, (search for NCT00129259)

funded by the Immune

Tolerance Network and

NIAID, will evaluate

patients with recent-

onset type 1 diabetes

mellitus (less than

or equal to 6 weeks

from diagnosis) ages

8-30 with treatment at

the start of the study

and again at one year

Delay Study Led by Dr. Kevan Herold http://www.clinicaltrials.gov

of Yale University, (search for NCT00378508)

this Phase 2 trial funded

by NIDDK is for patients

ages 8-30 with type 1

'/>"/>

SOURCE MacroGenics, Inc. Copyright©2007 PR Newswire.

1 GOOD